July/August 2012
World Intellectual Property Review
This article discusses how pharmaceutical companies develop a winning strategy to defend their diverse portfolio of patents and the different strategies they implement. Finnegan partner James B. Monroe, speaks to claims covering chemical compounds, the difference in litigation strategies between generic and innovator companies, and the 30-month stay.
Press Release
October 6, 2026
Commentary
Federal Circuit Revives Whistleblower Complaint Over VA's AI Claims-Processing Tool
September 25, 2026
Award/Ranking
Finnegan Named an IP Litigation Powerhouse in BTI Litigation Outlook 2027
September 24, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Press Release
Finnegan Secures Precedential Pro Bono Federal Circuit Victory for AI Whistleblower
September 23, 2026
Commentary
New Thomas Pink Womenswear Lines Strain ‘Pink’ Pact with Victoria’s Secret
September 21, 2026
Commentary
Pepsi's U.S. Trademark Dispute Could Reshape Brand Choices, Lawsuit Strategy, Lawyers Say
September 17, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.